Interestingly, combinatorial therapy of anti-PD-L1 and NK cell activating cytokines significantly augments the activity of NK cells against PD-L1 negative leukemia cells, thus potentially explaining the clinical response of PD-L1 negative cancers to PD-L1 inhibition [32,67]. This evidence concerns the gene CD274 and cancer.